Skip to content

Pasadena Star News

58°F
Friday, January 2nd 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CytomX Therapeutics, Inc. - Common Stock (NQ:CTMX)

4.295 +0.035 (+0.82%)
Streaming Delayed Price Updated: 1:27 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CytomX Therapeutics, Inc. - Common Stock

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Via Investor Brand Network
News headline image
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
Stocks Under $1 to Watch: TAOP, WLGS, HIT, CTMX, JYD – Major Updates, Earnings & Offerings, More Inside….
Via AB Newswire
Topics Economy
Breaking on The Street Stocks To Watch Now! CTMX, PRSO, IMCC, KAVL, VTAK
Via AB Newswire
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2023 – USA News Group – Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs... 
Via FinancialNewsMedia
News headline image
CytomX Therapeutics (NASDAQ: CTMX) and Regeneron (NASDAQ: REGN) Enter into Strategic Collaboration to Develop Bispecific Therapies to Treat Cancer
CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a clinical-stage biopharmaceutical company, which is focused on developing innovative treatments for a wide-range 
Via Spotlight Growth
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.